2026 ICD-10-CM Diagnosis Code E88.14HIV-associated lipodystrophy
E88.14 is a billable ICD-10-CM diagnosis code for HIV-associated lipodystrophy. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026).
Code Identity
Code Classification
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Code First
- any human immunodeficiency virus HIV disease B20
Use Additional Code
- code for adverse effect, if applicable, to identify drug T37.5X5
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, the ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation. Wherever such a combination exists, there is a "use additional code" note at the etiology code, and a "code first" note at the manifestation code. These instructional notes indicate the proper sequencing order of the codes, etiology followed by manifestation.
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Lipodystrophy - E88.10
- HIV-associated - E88.14
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Lipodystrophy
- HIV-associated
Clinical InformationClinical
Acquired Partial Lipodystrophy
partial lipodystrophy, the cause of which is not present at birth. examples include lipodystrophy associated with human immunodeficiency virus (hiv) therapy, and barraquer-simons syndrome, associated with c3 nephritic factor.Homeostatic Model Assessment of Insulin Resistance
an assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome
a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.Insulin Receptor Mutation - Associated Insulin Resistance Syndromes
insulin resistance caused by inactivating mutation(s) in the insr gene encoding the insulin receptor.Insulin Resistance
decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance
the determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.Insulin Resistance Syndrome
a cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. these abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome
a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.Obesity-Associated Insulin Resistance
insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.Acquired Generalized Lipodystrophy
generalized lipodystrophy, the cause of which is not present at birth.
Code History & ChangesHistory
New Code E88.14 was added to the ICD-10-CM code set for FY 2026, effective October 1, 2025.
Replacement E88.14 replaces the following previously assigned code(s):
- E88.1 - Lipodystrophy, not elsewhere classified
Questions About E88.14Overview
Is E88.14 (Lipodystrophy, not elsewhere classified) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report HIV-associated lipodystrophy on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
